Nutriband Celebrates Nasdaq Anniversary as AVERSA™ Fentanyl Nears IND Filing — Nutriband Inc.

Event summary

Nutriband marks five years since its Nasdaq uplisting on October 1, 2021, with AVERSA™ Fentanyl advancing toward IND filing.
2021–2022: Raised $8.7M in uplisting, partnered with Kindeva for AVERSA™ Fentanyl development, expanded pipeline to include Buprenorphine and Methylphenidate.
2023: Secured new IP, launched Active Intelligence brand with Donovan McNabb, converted $2M debt to equity.
2024: Signed commercial agreement with Kindeva, extended patents to 46 countries, reported $645,796 Q3 revenue.
2025: Completed FDA Type C meeting, issued 25% Preferred Stock dividend, added to Russell indexes.

The big picture

Nutriband's Nasdaq anniversary underscores its transition from feasibility to commercial development, with AVERSA™ Fentanyl poised as a potential first-of-its-kind abuse-deterrent opioid patch. The company's strategic focus on non-dilutive financing and patent expansion reflects broader trends in biotech capital efficiency and regulatory engagement. With warrants expired and a cleaner capital structure, Nutriband aims to leverage its FDA engagement and Kindeva partnership to drive shareholder value through clinical and commercial milestones.

What we're watching

Regulatory Milestones: The pace at which AVERSA™ Fentanyl advances through IND filing and FDA approval will determine commercialization timelines.
Execution Risk: Whether Nutriband can sustain its disciplined capital structure while funding clinical development and commercial scale-up.
Market Positioning: How AVERSA™ technology differentiates in the abuse-deterrent opioid market against competitors and generic alternatives.